A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant mutant form, offering a promising strategy for treating hematological ...

“As a highly potent and selective PARP1 inhibitor, it is expected that saruparib could lead to a safer profile that facilitates its combination with chemotherapy or other targeted agents ...

Nimbus Therapeutics announces the identification of an HPK1 inhibitor with highly potent and selective anti-tumor activity in preclinical models.

today announced that it has successfully discovered a potent, selective, and orally bioavailable small molecule inhibitor of CDK8 for the treatment of cancer using a structure-based generative ...

Background: SY-5609 is an oral, reversible, potent, and selective inhibitor of CDK7, a key regulator of transcription and cell cycle, currently under investigation in a Phase 1 study in patients (pts) ...